Antiprotozoal Lysophospholipid Analogues: A Comparison of their Activity Against Trypanosomatid Parasites and Tumor Cells

Title: Antiprotozoal Lysophospholipid Analogues: A Comparison of their Activity Against Trypanosomatid Parasites and Tumor Cells

Volume: 4 Issue: 2

Author(s): S. L. de Castro, R. M. Santa-Rita, J. A. Urbina and S. L. Croft

Affiliation:

Keywords: Antiprotozoal, Lysophospholipid, Trypanosoma cruzi, leishmaniasis

Abstract: Lysophospholipid analogues (LPAs), originally developed as anti-cancer agents, have shown significant activity against Leishmania spp. and Trypanosoma cruzi, both in vitro and in vivo. Miltefosine, used as a topical formulation (Miltex™) for metastases, was registered in 2002 for the oral treatment of visceral leishmaniasis. LPAs interfere with lipid synthesis in T. cruzi and cancer cells, but the activity is about > 20- fold higher against the parasite.

Cite this article as:

de Castro L. S., Santa-Rita M. R., Urbina A. J. and Croft L. S., Antiprotozoal Lysophospholipid Analogues: A Comparison of their Activity Against Trypanosomatid Parasites and Tumor Cells, Mini-Reviews in Medicinal Chemistry 2004; 4 (2) . https://dx.doi.org/10.2174/1389557043487439